ReviewJournal of gastrointestinal cancer2020
The Importance of AFP in Liver Transplantation for HCC.
Review in Journal of gastrointestinal cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- TrxR1 inhibition sensitizes hepatocellular carcinoma to Motesanib via an autophagy-ROS-JNK/ER stress axis.Biology direct · 2026Article
- Redefining Liver Transplantation Indications for Hepatic Malignancies in the Era of Precision Transplant Oncology: An Up-to-Date Narrative Review.Journal of clinical medicine · 2026Review
- Development and validation of a nomogram based on tumor margin irregularity and alpha-fetoprotein for predicting microvascular invasion in hepatocellular carcinoma.Frontiers in oncology · 2026Article
- Survival outcomes of patients after liver transplantation for patients with hepatocellular carcinoma exceeding the Hangzhou criteria.Journal of gastrointestinal oncology · 2025Article
- Gallbladder Schwannoma: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- Precision medicine in liver transplantation for hepatocellular carcinoma: applications and prospects of third-generation sequencing technology.Journal of cancer research and clinical oncology · 2025Review
- FCGR2A contributes to M2 macrophages polarization in HCC through IL-4/JAK/STAT6 axis.Translational oncology · 2025Article
- Bioinformatics identification of key microRNA-correlated genes associated with hepatocellular carcinoma heterogeneity and prognosis.BMC gastroenterology · 2025Article
- Clinical significance of immune cell and biomarker changes in liver cancer.World journal of gastrointestinal surgery · 2025Article
- Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation.Clinical and molecular hepatology · 2025Review
- Serum miRNA-101 expression signature as non-invasive diagnostic biomarker for Hepatitis C virus-associated hepatocellular carcinoma in Egyptian patients.Scientific reports · 2025Article
- Comparative Effectiveness and Safety of Molecular Targeted Therapy Plus PD-(L)1 with or without TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Study.ImmunoTargets and therapy · 2025Article
- To explore the prognostic efficacy and mechanism of ABCC5 clinical scoring model in hepatocellular carcinoma.Frontiers in oncology · 2025Article
- A predictive model based on radiomics, clinical features, and pathologic indicators for disease-free survival after liver transplantation for hepatocellular carcinoma: a 7-year retrospective study.Journal of gastrointestinal oncology · 2024Article
- Discovering novel prognostic biomarkers of hepatocellular carcinoma using eXplainable Artificial Intelligence.Expert systems with applications · 2024Article
- Metabolomics Biomarker Discovery to Optimize Hepatocellular Carcinoma Diagnosis: Methodology Integrating AutoML and Explainable Artificial Intelligence.Diagnostics (Basel, Switzerland) · 2024Article
- Pan‑immune‑inflammation value as a novel prognostic biomarker in nasopharyngeal carcinoma.Oncology letters · 2024Article
- Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors.World journal of gastroenterology · 2024Article
- Development of a deep learning model for predicting recurrence of hepatocellular carcinoma after liver transplantation.Frontiers in medicine · 2024Article
- Diagnosis and treatment of hepatocellular carcinoma with pelvic metastasis expressing AFP: a case report.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe most common biomarker for HCC is serum alpha-fetoprotein (AFP). AFP is used for screening and diagnosing HCC, and also, it is used for predicting prognosis and monitoring the response to treatment. DISCUSSION: AFP secretion is associated with poor tumor histologic grade and aggressive tumor biological behavior. The risk of dropout on the waiting list for liver transplantation and the risk of tumor recurrence after liver transplantation are associated with high AFP serum levels. Therefore, using AFP levels for selecting patients to include on the liver transplantation waiting lists is critical. It is also known that a low AFP serum level before liver transplantation has limited informative value, but high AFP levels prior to liver transplantation indicate a higher risk for HCC recurrence.
conclusionAFP's performance as a screening, diagnostic, and prognostic marker for HCC is not ideal, but it is the most frequently used biomarker in the management of HCC.
Indexed as
Identifiers
32845425What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.